Bresat Cancer Update
Oncology Leader CommentarySpecial FeaturesPrevious Issues

Home: Oncology Leader Commentary: Gershon Locker, MD

Click on the topic below for comments by Dr Gershon Locker to comment on. You will also find links to related articles and clinical trials.

Trials of first line Arimidex
Choosing first-line endocrine therapy in postmenopausal patients
Vasomotor symptoms and Arimidex
Mechanisms of resistance to endocrine therapy
Tamoxifen rechallenge versus Arimidex
Aromatase inhibitors when adjuvant tamoxifen is contraindicated
ATAC adjuvant trial: Arimidex vs Tamoxifen vs the Combination

Tamoxifen rechallenge versus Arimidex

Interview with Neil Love, MD from Breast Cancer Update for Medical Oncologists, Program 1 2000

Play Audio Below:

The only time that tamoxifen is an issue for first-line metastatic disease is in the scenario where they were off tamoxifen for several years. Do you put them on or do you put them on Arimidex? And, until recently I was putting them back on tamoxifen. Now I’ll put them on Arimidex. But, there are so few ER-positive patients with metastatic disease who haven’t seen adjuvant tamoxifen that it’s almost a moot point. I think the study is important to tell us how good Arimidex is, to tell us that Arimidex should be looked in the adjuvant setting, which it was. And to tell us, if you have a woman who is prescribed tamoxifen for some reason and has a side effect or her hairdresser has told her that the drug is terrible, put her on Arimidex. – period.

Top of Page

Home · Contact us
Terms of use and general disclaimer